FDA approves new standard of care for kidney cancer
The FDA granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. The results of the large, international clinical trial leading to the approval were published the New England Journal of Medicine. April 16, 2018